EDGE
SIGN4L, a dynamic provider of agile and adaptive electronic warfare and intelligence (EW&I) solutions, today launched two state-of-the-art solutions that are set to offer a tactical advantage in the missions of tomorrow. V-Protect, a radio frequency (RF) communication jamming system, and NavControl-G, a specialised counter-drone capability, are well positioned to become game-changers in shaping favourable outcomes in an increasingly digitalised defence landscape.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210221005031/en/
The solutions were unveiled at the EDGE pavilion at the ongoing International Defence Exhibition and Conference (IDEX 2021) that runs until 25 February at the Abu Dhabi National Exhibition Centre (ADNEC).
V-Protect is an advanced mobile active and reactive high-power jammer system aimed at helping block common terrestrial RF signal technologies as well as portable satcom equipment, spanning radio, walkie-talkie, mobile and Wi-Fi frequencies. Boasting a counter-improvised explosive device (C-IED) and counter-drone measures, the user-friendly model is to be installed in a standard SUV and offers automatic operability by utilizing 16 channels and high emitting power amplifiers to provide support in enhancing protection range and combatting various threats across the frequency domain.
NavControl-G is a sophisticated transmitter unit designed to help prevent unmanned aerial vehicles (UAVs) from trespassing into specific locations. To help safeguard a sensitive area, the system can emulate GPS signals to generate position and timing inaccuracies, thereby taking control of non-cooperating unmanned vehicles. Encased in a shock-proof container, the system can be seamlessly integrated across multiple configurations - either in fixed locations or deployed on the field when required.
Waleid Al Mesmari, Vice President of Program Management for the Electronic Warfare & Intelligence cluster at EDGE, said: “Electronic warfare and intelligence make up the backbone of modern defence and security systems. SIGN4L is at the frontlines in pioneering breakthrough technologies that help our clients expand their options in a rapidly changing world. By assisting our clients with the management of their complex security and performance requirements, our latest solutions are prime examples of our agile offerings at work that focus energy to obscure, neutralise and attack adversaries.”
SIGN4L brings a startup ethos to designing and producing state-of-art open-architecture digital and RF-based security products and services for governments and businesses in the region. The company has implemented a rigorous cycle of threat analysis, research, and development to monitor, analyse and counter emerging risks. SIGN4L is part of the Electronic Warfare & Intelligence cluster at EDGE, an advanced technology group that ranks among the top 25 military suppliers in the world.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20210221005031/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom